VOLUME 1 · NUMBER 1 · FEBRUARY 1987

R. E. Pounder, M. J. S. Langman: Editorial Introduction 1

A. K. Burroughs, D. Sprengers, P. A. McCormick: Review article: β-adrenoceptor blockers for the treatment of portal hypertension 3

J. R. Reynolds, R. P. Walt, A. G. Clark, J. D. Hardcastle, M. J. S. Langman: Intragastric pH monitoring in acute upper gastrointestinal bleeding and the effect of intravenous cimetidine and ranitidine 23

G. N. J. Tytgat, C. B. H. W. Lamers, W. Hameeteman, J. M. B. J. Jansen, J. A. Wilson: Omeprazole in peptic ulcers resistant to histamine H_2-receptor antagonists 31

M. C. Allison, R. E. Pounder: Cyclosporin for Crohn's disease 39

H. S. Fuessl, J. Domin, J. V. Anderson, S. R. Bloom: Chronic administration of the somatostatin analogue SMS 201-995 does not lead to endogenous antibody formation 45

B. J. Z. Danesh, L. M. Nelson, R. I. Russell, C. Docherty: Replacing the acetyl linkage in aspirin with choline and magnesium moieties reduces the occurrence of gastric mucosal injury 51

E. J. S. Boyd, D. A. Johnston, K. G. Wormsley, W. N. Jenner, X. Salanson: The effects of cigarette smoking on plasma concentrations of gastric antisecretory drugs 57

B. Sharma, M. Axelson, R. E. Pounder, P. Lundborg, M. Öhman, A. Santana, M. Talbot, C. Cederberg: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects 67

VOLUME 1 · NUMBER 2 · APRIL 1987

A. H. Soll: Review: antisecretory drugs—cellular mechanisms of action 77

K. Lauritsen, J. Rask-Madsen: Review: clinical trials in peptic ulcer disease—problems of methodology and interpretation 91

C. J. De Gara, D. W. Burget, A. N. Chremos, C. Silletti, R. H. Hunt: The effects of intravenous famotidine on pentagastrin-stimulated gastric secretion in man 125

A. P. Savage, J. Calam, C. B. Wood, S. R. Bloom: SMS 201–995 treatment and advanced intestinal cancer: a pilot study 133

W. Beil, P. Stünkel, A. Pieper, K.-Fr. Sewing: The gastric proton pump, a target for neuroleptics and antidepressant drugs? 141

M. Allen, M. Mellow, M. G. Robinson, W. C. Orr: Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function 153

R. P. Walt, R. E. Pounder, C. J. Hawkey, I. A. Santana, K. W. Somerville, R. F. A. Logan, R. G. Long, M. J. S. Langman: Twenty-four-hour intragastric acidity and clinical trial of bedtime enprostil 70 μg compared with ranitidine 300 μg in duodenal ulcer 161

VOLUME 1 · NUMBER 3 · JUNE 1987

D. G. Colin Jones, M. J. S. Langman, D. H. Lawson, M. B. Vessey: Review: post-marketing surveillance of the safety of cimetidine—the problems of data interpretation 167

H. Ruppin: Review: loperamide—a potent antidiarrhoeal drug with actions along the alimentary tract 179

R. G. Long: Review: long-acting somatostatin analogues 191

D. A. Burke, A. P. Manning, J. M. S. Williamson, A. T. R. Axon: Adverse reactions to sulphasalazine and 5-aminosalicyclic acid in the same patient 201

J. G. Hardy, J. N. C. Healey, S. W. Lee, J. R. Reynolds: Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicyclic acid tablet 209
H. S. Merki, L. Witzel, R. P. Walt, J. Neumann, E. Scheurle, D. Kaufmann, A. Mappes, J. Heim, J. Röhmel: Comparison of ranitidine 300 mg twice daily, 300 mg at night and placebo on 24-hour intragastric acidity of duodenal ulcer patients 217
S. Lanzon-Miller, R. E. Pounder, M. R. Hamilton, N. A. F. Chronos, S. Ball, J. E. Mercieca, M. Olausson, C. Cederberg: Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer or pernicious anaemia 225
S. Lanzon-Miller, R. E. Pounder, M. R. Hamilton, S. Ball, N. A. F. Chronos, F. Raymond, M. Olausson, C. Cederberg: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole 239
C. W. Brook, N. D. Yeomans, E. G. Hewson, R. A. Smallwood: Gastric acid secretory capacity falls under repeated within-day pentagastrin testing in fed subjects 253

VOLUME 1 · NUMBER 4 · AUGUST 1987

R. E. P. Pounder, M. J. S. Langman: Letter from the Editors 261
N. P. Kennedy, P. W. N. Keeling: Review: lipoxygenase inhibitors and the gut 263
J. G. Hardy, J. N. C. Healey, J. R. Reynolds: Evaluation of an enteric-coated delayed-release 5-aminosalicyclic acid tablet in patients with inflammatory bowel disease 273
C. T. Richardson, C. C. Barnett, J. H. Walsh, M. Feldman: Comparison of two anti-muscarinic drugs, pirenzipine and propantheline, on gastric acid secretion, salivary flow and heart rate in patients with duodenal ulcer disease 281
B. Krevsky, L. S. Malmud, A. H. Maurer, M. B. Somers, J. A. Siegel, R. S. Fisher: The effect of oral cisapride on colonic transit 293
C. W. Howden, D. W. Burget, C. Silletti, A. Van Eeden, K. B. Tomkins, R. H. Hunt: Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE_1 analogue 305
M. G. Brook, A. A. Dunk, J. A. McDonald, A. M. Lever, C. Goh, H. C. Thomas: Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas 315
H. S. Fussl, J. M. Burrin, G. M. Williams, T. E. Adrian, S. R. Bloom: The effect of a long-acting somatostatin analogue (SMS 201–995) on intermediary metabolism and gut hormones after a test meal in normal subjects 321
K. J. Fotherby, J. O. Hunter: Idiopathic slow-transit constipation: whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonists 331

VOLUME 1 · NUMBER 5 · OCTOBER 1987

D. J. Back, S. M. Rogers: Review: first-pass metabolism by the gastrointestinal mucosa 339
H. J. F. Hodgson: Review: gut sterilization in inflammatory bowel disease 359
M. J. S Langman: Editorial comment 367
R. L. McIsaac, I. McCanless, K. Summers, J. R. Wood: Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials 369

D. L. HOGAN, F. J. THOMAS, J. I. ISENBERG: Cimetidine decreases aspirin-induced gastric mucosal damage in humans 383
C. A. RODRIGUES, E. M. NABI, C. SPILIADIS, P. B. MCINTYRE, V. PHONGSATHORN, J. E. LENNARD-JONES, A. ROSEN, J. M. T. WILLOUGHBY: Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent 391
L. A. HOUGHTON, N. W. READ: A comparative study of the effect of cimetidine and ranitidine on the rate of gastric emptying of liquid and solid test meals in man 401
D. W. BULLIMORE, B. A. MULLEY, P. COOKE, K. J. A. MILOSZEWSKI: Comparison of the effectiveness of midazolam and diazepam in lipid emulsion as sedation during upper gastrointestinal endoscopy 409
R. STOLL, H. STERN, H. RUPPIN, W. DOMSCHKE: Effect of two potent calmodulin antagonists on calcium transport of brush border and basolateral vesicles from human duodenum 415
I. MCL. WELCH, A. J. BAXTER, N. W. READ: Effect of naloxone, domperidone and idazoxan on the delay in gastric emptying induced by ileal lipid 425

VOLUME 1 · SUPPLEMENT 1 · 1987

F. HALTER, F. EIGENMANN: Is it really more difficult to treat prepyloric ulcers? 433S
R. E. POUNDER: What is an intractable duodenal ulcer and how should it be managed? 439S
J. I. ISENBERG: The impact of H_2-receptor antagonists on the complications, morbidity and mortality of peptic ulcer disease. 447S
C. P. SWAIN: When and why do ulcers bleed and what can be done about it? 455S
H. G. DAMMANN, TH. A. WALTER, M. DREYER, B. DAU, P. MÜLLER, B. SIMON: What are the current possibilities in treating peptic ulcer disease? 468S
W. SCHUNACK: What are the differences between the H_2-receptor antagonists? 495S
S. G. MANN: The place of famotidine in anti-ulcer therapy. 504S
J. J. MISIEWICZ: What is new in the epidemiology and pathogenesis of peptic ulcer? 510S
R. BUMM, A. L. BLUM: Lessons from prolonged gastric pH monitoring. 518S
G. N. J. TYTGAT, E. A. J. RAUWS: Significance of *Campylobacter pylori*. 527S
G. BIANCHI PORRO, F. PACE, I. CARUSO: Why are non-steroidal anti-inflammatory drugs important in peptic ulceration? 540S
D. G. COLIN-JONES. When should endoscopy (or radiology) be used in dyspepsia and peptic ulcer disease? 548S
Panel discussions. 556S

VOLUME 1 · NUMBER 6 · DECEMBER 1987

P. L. ZENTLER-MUNRO, T. C. NORTHFIELD: Review: pancreatic enzyme replacement—applied physiology and pharmacology 575
C. J. HAWKEY: Review: acute human models of gastric mucosal injury 593
T. M. FEELEY, A. S. CLANACHAN, G. W. SCOTT: Contractility of human gallbladder muscle *in vitro* 607
I. A. TAVARES, P. O. COLLINS, A. BENNETT: Inhibition of prostanoid synthesis by human gastric mucosa 617
T. K. CHAKRABORTY, J. S. DE CAESTECKER, A. PRYDE, R. C. HEADING: Effect of omeprazole on lower oesophageal function in normal subjects 627

A. G. Morgan, C. Pacsoo, P. Taylor, W. A. F. McAdam: Does Caved-S decrease the gastric ulcer relapse rate during maintenance treatment with ranitidine? 633

P. Macmathuna, T. O'Reilly, D. Kelleher, M. Barry, J. Feely, P. W. N. Keeling: The effect of calcium channel blockade with nifedipine on splanchnic and systemic haemodynamics in cirrhosis 639

A. Prior, P. J. Whorwell: Effect of nicardipine on gastric acid secretion in man 643

A. J. Baxter, C. A. Edwards, S. Holden, K. M. Cunningham, I. McL. Welch, N. W. Read: The effect of two α_2-adrenoreceptor agonists and an antagonist on gastric emptying and mouth to caecum transit time in humans 649